



Leveraging CGM to its Full Potential in People with T2D

Adams K. The CGM adoption gap is worse than you think. MedCity News. December 28, 2025. Available at: https://medcitynews.com/2025/12/cgm-diabetes-healthcare/?utm_medium=email&_hsenc=p2ANqtz-8Ezp9Cx2wT5cCEl-bbR7sKwnmQB6W_OlidG8j-B47K03dXtOVMXme0vIapw7_8Au3fswCJ-KXN-98jZ_0xrJvWsOUPF4jNLAXpwf-qzX-HxWtPAqY&_hsmi=396267052&utm_content=396267052&utm_source=hs_email. Accessed March 27, 2026.

Adolfsson P, Parkin CG, Thomas A, Krinelke LG. Selecting the Appropriate Continuous Glucose Monitoring System - a Practical Approach. *Eur Endocrinol*. 2018;14(1):24-29.

Ali SN, Dang-Tan T, Valentine WJ, Hansen BB. Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States. *Adv Ther*. 2020;37(2):869-882.

American Diabetes Association Professional Practice Committee for Diabetes*; 7. Diabetes Technology: Standards of Care in Diabetes—2026. *Diabetes Care*. 2026;49(Supplement_1):S150-S165.

Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care*. 2019;42(8):1593-1603.

Beck RW, Riddlesworth T, Ruedy K, et al; DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. *JAMA*. 2017;317(4):371-378.

Brown RE, Chu L, Norman GJ, Abitbol A. Real-world glycaemic outcomes in adult persons with type 1 diabetes using a real-time continuous glucose monitor compared to an intermittently scanned glucose monitor: A retrospective observational study from the Canadian LMC diabetes registry (REAL-CGM-T1D). *Diabet Med*. 2022;39(11):e14937.

Centers for Medicare & Medicaid Services. Glucose Monitors (L33822). Available at: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33822>. Accessed March 27, 2026.

Corathers SD, DeSalvo DJ. Therapeutic Inertia in Pediatric Diabetes: Challenges to and Strategies for Overcoming Acceptance of the Status Quo. *Diabetes Spectr*. 2020;33(1):22-30.



Leveraging CGM to its Full Potential in People with T2D

Dowd R, Jepson LH, Green CR, et al. Glycemic Outcomes and Feature Set Engagement Among Real-Time Continuous Glucose Monitoring Users With Type 1 or Non-Insulin-Treated Type 2 Diabetes: Retrospective Analysis of Real-World Data. *JMIR Diabetes*. 2023;8:e43991.

Fang M, Wang D, Coresh J, Selvin E. Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018. *N Engl J Med*. 2021;384(23):2219-2228.

Garber AJ, Handelsman Y, Grunberger G, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm. *Endocr Pract*. 2020;26(1):107-139.

Gavin JR, Bailey CJ. Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen. *Diabetes Technol Ther*. 2021;23(3_suppl):S-19-S-27.

Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. *Diabetes Care*. 2013;36(11):3411-3417.

Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). *Diabetes Care*. 2019;42(3):416-426.

Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. *JAMA*. 2017;317(4):379-387.

Martens TW, Parkin CG. How use of continuous glucose monitoring can address therapeutic inertia in primary care. *Postgrad Med*. 2022;134(6):576-588.

Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. *JAMA*. 2021;325(22):2262-2272.

Miller EM. Using Continuous Glucose Monitoring in Clinical Practice. *Clin Diabetes*. 2020;38(5):429-438.



Leveraging CGM to its Full Potential in People with T2D

Oser TK, Hall TL, Dickinson LM, et al. Continuous Glucose Monitoring in Primary Care: Understanding and Supporting Clinicians' Use to Enhance Diabetes Care. *Ann Fam Med*. 2022;20(6):541-547.

Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, et al. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. *Diabetologia*. 2018;61(3):539-550.

Pratley RE, Kanapka LG, Rickels MR, et al; Wireless Innovation for Seniors With Diabetes Mellitus (WISDM) Study Group. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. *JAMA*. 2020;323(23):2397-2406.

Simonson GD, Holt EH, Grady M, et al. Unleashing the Potential of Blood Glucose Monitoring Data With the Ambulatory Glucose Profile Report. *Clin Diabetes*. 2024;42(4):550-560.

Unger J, Kushner P, Anderson JE. Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care. *Postgrad Med*. 2020;132(4):305-313.

van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. *Lancet Diabetes Endocrinol*. 2016 ;4(11):893-902.

Ziemer DC, Miller CD, Rhee MK, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. *Diabetes Educ*. 2005;31(4):564-571.